Preclinical Development of HIV-1 Vif Antagonists

Project: Research project

Description

DESCRIPTION (provided by applicant): The objective of this program project application is to develop novel therapeutics that target CNS and peripheral reservoirs of HIV-1 replication. Under the auspices of a U19, we have identified novel small molecules that target the vif-apobec axis and that specifically inhibit vif-dependent viral replication. Structure Activity Relationship (SAR studies have identified potent analogs (IC50
StatusFinished
Effective start/end date8/19/137/31/19

Funding

  • National Institutes of Health: $1,168,508.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,181,526.00
  • National Institutes of Health
  • National Institutes of Health: $1,237,491.00
  • National Institutes of Health
  • National Institutes of Health: $1,194,404.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,262,306.00

Fingerprint

HIV-1
Structure-Activity Relationship
Inhibitory Concentration 50
Antiviral Agents
Macrophages
Macaca
Therapeutics
Mutation
Viral RNA
Drug Discovery
intellectual property
Research Personnel
Viruses